

13 February 2026

# BIOXYNE HALF YEAR FY26 RESULTS INVESTOR WEBINAR

**Bioxyne Limited (ASX: BXN) (“Bioxyne” or “the Company”)** is hosting an investor webinar to discuss its **H1 FY26 Results**, which are anticipated for release on Thursday, 26 February 2026.

## CALL DETAILS

Date: Thursday, 26 February 2026

Time: 11:00AM AEDT / 8:00AM AWST

Register for the investor webinar at the link here:

[Bioxyne Half Yearly Conference Call Registration Link](#)

After registering, you will receive a confirmation email containing information about joining the webinar.

A recording of the conference call will be made available via Bioxyne’s website at <https://bioxyne.com/>.

**Approved by the Board of Bioxyne Limited for release to the ASX.**

For further information, please contact:

Bioxyne Limited  
Sam Watson  
Chief Executive Officer  
[info@bioxyne.com](mailto:info@bioxyne.com)

NWR Communications  
Melissa Tempura  
Media & Investor Relations  
[melissa@nwrcommunications.com.au](mailto:melissa@nwrcommunications.com.au)



## About Bioxyne Ltd.

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.

## About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Scotland (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of the Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognised for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription-only medicines.
- b) Contract medicine manufacture and white label manufacture of medicinal products for human use.
- c) Wholesale distribution, import and export of controlled drugs, finished medicinal products, and active pharmaceutical ingredients.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®

**United Kingdom:** [drwatsoncbd.com](https://drwatsoncbd.com)

**UK / EU:** [breathelifesciences.com](https://breathelifesciences.com)

- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: [bioxyne.com](https://bioxyne.com)

Australia: [bls.com.au](https://bls.com.au)

International: [breathelifesciences.com](https://breathelifesciences.com)